Table 4.

Adverse events.

Adverse events	Hybutimibe plus atorvastatin (n = 127)		Atorvastatin (n = 125)
	n	Patients (%)	n	Patients (%)
Total	173	65 (51.18)	159	77 (61.60)
Adverse events leading to suspension of the trial	6	5 (3.94)	12	10 (8.00)
Serious adverse events	8	7 (5.51)	9	9 (7.20)
Adverse events resulting in death	0	0 (0.00)	0	0 (0.00)
Drug-related adverse events	17	10 (7.87)	18	17 (13.60)
Drug-related adverse events that led to the suspension of the trial	3	2 (1.57)	6	6 (4.80)
Serious adverse events related with study drugs	0	0 (0.00)	1	1 (0.80)
Drug-related adverse events leading to death	0	0 (0.00)	0	0 (0.00)